Zevra Therapeutics Announces FDA Acceptance of IND Application for KP1077 in Narcolepsy
May 03, 2023 07:30 ET
|
Zevra Therapeutics
Zevra plans to expand KP1077 clinical program to address multiple rare sleep disorders with trials initiating in 2023 CELEBRATION, Fla., May 03, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc....
Leading Proxy Advisory Firms ISS and Glass Lewis Demonstrate Strong Support for Zevra’s Transformation Strategy
April 17, 2023 16:05 ET
|
Zevra Therapeutics
Glass Lewis Recommends a Vote “FOR” Zevra’s Three Nominees Both ISS and Glass Lewis Recommend Shareholders DO NOT Vote “FOR” Any of the Mangless Nominees Zevra Urges Shareholders to Vote on the...
Zevra Therapeutics Announces Submission of IND for KP1077 in Narcolepsy
April 04, 2023 07:30 ET
|
Zevra Therapeutics
Zevra seeks to expand KP1077 clinical program to address multiple rare sleep disorders CELEBRATION, Fla., April 04, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra” or...
Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors
March 30, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced...
Zevra Therapeutics Announces Collaboration with RARE-X and the Sleep Consortium as Founding Member of New Sleep Data Initiative
March 17, 2023 07:30 ET
|
Zevra Therapeutics
New Patent Issued Covering Serdexmethylphenidate (SDX), the Sole Active Pharmaceutical Ingredient in KP1077, Zevra’s Product Candidate for the Treatment of Idiopathic Hypersomnia (IH) CELEBRATION,...
Zevra Therapeutics Files Definitive Proxy Statement and Mails Letter to Shareholders
March 15, 2023 07:26 ET
|
Zevra Therapeutics
Urges Shareholders to Vote "FOR" All Zevra Director Nominees on the WHITE Proxy Card CELEBRATION, Fla., March 15, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NasdaqGS: ZVRA) (“Zevra” or the...
Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Updates
March 07, 2023 07:00 ET
|
Zevra Therapeutics
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, March 7, 2023, 8:30 a.m. ET Newly rebranded Zevra Therapeutics well positioned to become a commercially focused...
Zevra Therapeutics to Present at 35th Annual Roth Conference
March 06, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., March 06, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today...